PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. The offering is expected to close on June 2, 2026, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1...

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced results from a Phase Ib study evaluating olverembatinib (HQP1351), the company’s core product, in combination with bispecific T-cell engager antibody (immunotherapy) blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting is the world’s most...

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53 inhibitor from the Company’s apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs), in a rapid oral presentation at the 62nd American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting showcases cutting-edge research in clinical oncology and advanced cancer...

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting is the world’s most prominent scientific gathering in the clinical oncology community, showcasing cutting-edge research in clinical oncology and advanced...

Diana has released a video message from Chief Executive Officer Semiramis Paliou in which she speaks directly to Genco shareholders about the value of Diana’s offer, the case for board change, and the importance of acting immediately.Details Why the Entrenched Genco Board Should Not Be Trusted to Act in Shareholders’ Best Interests Contrasts Diana’s Six Accomplished, Independent Nominees Against a Board That Has Spent Six Months and Over $13 Million Protecting Itself and Management Releases Video Message to Genco Shareholders from CEO Semiramis Paliou Outlining the Compelling Value of Diana’s Offer and the Urgent Need for Board Change Calls on Genco Shareholders to Elect a Board That Will Finally Put Shareholders First by Voting the GOLD Universal Proxy Card “FOR” Diana’s Six...

Worldwide Fans Invited to Follow Live at https://lpl.flashsportsandmedia.com LPL Season 6 player auction to take place June 1, 2026, ahead of the July–August 2026 tournament; fans and investors can visit theipggroup.com, LPL for live auction updates, event schedules, and franchise information; UGRO positioned across LPL media, sponsorship, and activation economics through subsidiary Innovative Production Group FZ, LLC LAFAYETTE, Colo., May 31, 2026 (GLOBE NEWSWIRE) — urban-gro, Inc. (Nasdaq: UGRO) (“urban-gro” or the “Company”), operating through Flash Sports & Media, Inc., today announced that the Lanka Premier League (“LPL”) Season 6 Player Auction is scheduled for June 1, 2026, 5:00 AM EDT (2:30 PM Colombo Time) marking a key milestone in the build-up to the sixth edition of the tournament,...

KALDVIK AS (KLDVK) reports Operating income in Q1 amounted to EURm 36.5 (EURm 48.4), while the operating loss before fair value adjustment of biomass and production tax was EURm -26.4 (EURm 9.8).  Harvest amounted to 6,441 (6,383) tonnes in Q1 2026. Kaldvík AS maintains harvest guidance for 2026 to approximately 17,000 tonnes. The Q1 2026 quarterly update presentation is attached. Kaldvik AS publishes full financial statements semi-annually (half-year and annual reports). Webcast A webcast presentation of the Q1 2026 quarterly update will be held at 15:00 CEST (13:00 Icelandic time) on 1 June 2026. The presentation will be held in English by CEO Vidar Aspehaug and CFO Hjalti Hvítklett. A Q&A session will follow. The webcast can be accessed at: http://www.kaldvik.is/live Contact: Hjalti Hvítklett, CFO+298 221 222 (mobile) This information...

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancerIn head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR of 8.8 months; all responders achieved deep responses with 60-100% tumor reductionIMA401 MAGEA4/8 TCR bispecific demonstrated favorable tolerability at RP2D with or without pembrolizumab, suggesting its potential for broad combinabilityIMA401 data will be presented in an oral presentation at the 2026 ASCO Annual Meeting and published simultaneously in Nature MedicineThe data support Immatics’ strategy to combine IMA401 with IMA402 (PRAME bispecific) in lung cancer and potentially other...

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 31 May 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative...